This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Pfizer Confirms AstraZeneca Interest

NEW YORK (The Deal) -- New York pharmaceuticals giant Pfizer (PFE) on Monday said it was considering making a renewed run at AstraZeneca AZN to strengthen its cancer treatments after a failed January approach and as rivals successfully expand their oncology businesses.

Pfizer said it hoped to offer AstraZeneca investors a "significant premium" after trying to lure AstraZeneca into talks with a 4,661 pence ($78.51) per-share offer, which it said represented a 30% premium for shareholders at the time. It envisages an offer in both cash and shares but said it may alter the final terms.

Although investors already pushed up the stock 7.9% last week amid reports of Pfizer's interest, AstraZeneca shares leapt 11.5%, or 481.50 pence, to 4,656.50 pence in Monday morning trading in London. That values the company at 58.8 billion pounds.

"We believe patients all over the globe would benefit from our shared commitment to R&D, which is critical to the future success of the pharmaceutical industry, in the form of potential new therapies that help to fight some of the world's most feared diseases, such as cancer," said Pfizer CEO and chairman Ian Read in a statement.

Drug companies the world over kicked off a consolidation a decade ago that has included a series of multi-billion dollar deals as manufacturers try to offset the loss of patents on blockbuster drugs. They've also spent to buy drug development companies and sold off less profitable assets.

Last week, Basel's Novartis (NVS) agreed to buy the oncology business of GlaxoSmithKline (GSK), adding impetus to Pfizer's ambitions. Novartis also wants to sell its vaccine business to GlaxoSmithKline and link its over-the-counter business with the buyer's. Novartis also announced a deal to sell its animal health division to Indianapolis-based Eli Lilly (LLY).

In another recent oncology-related deal, Germany's Bayer in December agreed to pay nearly $3 billion for Norwegian partner Algeta, which recently began marketing a prostate cancer treatment.

AstraZeneca has reportedly tapped Goldman, Sachs & Co. and Morgan Stanley to review any approaches.

Despite investor enthusiasm, analysts aren't so taken with Pfizer's plans.

"I view a takeover of AstraZeneca by the U.S. drug company exceptionally skeptically," wrote Deutsche Bank AG analyst Mark Clark in a note. He has a hold rating on AstraZeneca shares. Clark said AstraZeneca's oncology pipeline is too young to be of much help to Pfizer in the short term.

Meanwhile, Pfizer said combining with AstraZeneca would give it "industry-leading" treatments for various lung cancers as well as AstraZeneca's Faslodex, a breast cancer treatment in Phase 3 -- the final stage -- trials.

Pfizer said it also saw promise by combining their experimental oncology drugs and hoped to save money by combining non-overlapping activities.

A combined Pfizer and AstraZeneca would be based and listed in New York but have management in both New York and London, the company said.

AstraZeneca refused to comment.

Pfizer is taking financial advice from Bank of America Merrill Lynch's Fares Noujaim, Adrian Mee, Michael Findlay and Geoff Iles; a Guggenheim Securities LLC team of Alan Schwartz, Ken Springer and Jim Ferency; and JPMorgan Securities LLC's Steve Frank, Laurence Hollingworth, Mark Breuer and Christopher Dickinson.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,113.54 +61.81 0.36%
S&P 500 1,983.53 +9.90 0.50%
NASDAQ 4,456.0160 +31.3120 0.71%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs